India is one of the world’s largest suppliers of generic medicines and APIs to Europe. If the EU begins favouring “Made in EU” pharmaceutical production through procurement preferences, subsidies or state aid, Indian drug manufacturers could face reduced access to EU public procurement contracts and tougher supply-chain resilience requirements…
